Evidence map›Paper›PMID 27193941›Full record

ArticleTechnology in cancer research & treatment2017

Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results.

Mirko D'Onofrio, Stefano Crosara, Riccardo De Robertis, Giovanni Butturini, Roberto Salvia, Salvatore Paiella, Claudio Bassi, Roberto Pozzi Mucelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Endoscopic ultrasound-guided radiofrequency ablation in the treatment of pancreatic ductal adenocarcinoma: when science tries to increases hope.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mirko D'Onofrio1 Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Stefano Crosara1 Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Riccardo De Robertis1 Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Giovanni Butturini2 Department of Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Roberto Salvia2 Department of Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Salvatore Paiella2 Department of Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Claudio Bassi2 Department of Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy.
Roberto Pozzi Mucelli1 Department of Radiology, G.B. Rossi Hospital, University of Verona, Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe objective of this study was to evaluate the efficacy of percutaneous radiofrequency ablation of locally advanced pancreatic cancer located in the pancreatic body. MATERIALS AND

methodsPatients with biopsy-proven locally advanced pancreatic adenocarcinoma were considered for percutaneous radiofrequency ablation. Postprocedural computed tomography studies and Ca19.9 tumor marker evaluation were performed at 24 hours and 1 month. At computed tomography, treatment effect was evaluated by excluding the presence of complications. The technical success of the procedure is defined at computed tomography as the achievement of tumoral ablated area.

resultsTwenty-three patients have been included in the study. Five of the 23 patients were excluded. At computed tomography, the mean size of the intralesional postablation necrotic area was 32 mm (range: 15-65 mm). Technical success of the procedure has been obtained in 16 (93%) of the 18 cases. None of the patients developed postprocedural complications. Mean Ca19.9 serum levels 1 day before, 1 day after, and 1 month after the procedure were 285.8 U/mL (range: 16.6-942.0 U/mL), 635.2 U/mL (range: 17.9-3368.0 U/mL), and 336.0 U/mL (range: 7.0-1400.0 U/mL), respectively. Follow-up duration was less than 6 months for 11 patients and more than 6 months for 7 patients. At the time of the draft of this article, the mean survival of the patients included in the study was 185 days (range: 62-398 days).

conclusionPercutaneous radiofrequency ablation of locally advanced adenocarcinoma has a high technical success rate and is effective in cytoreduction both at imaging and laboratory controls.

Indexed as

AdenocarcinomaAgedAntigens, Tumor-Associated, CarbohydrateCatheter AblationFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsTomography, X-Ray ComputedTreatment OutcomeAntigens, Tumor-Associated, Carbohydratecarbohydrate antigen 199, humanpancreatic adenocarcinomapancreatic cancerRFARFA pancreasRFA percutaneous

Identifiers

PMID27193941
PMCPMC5616042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.